Senti Biosciences Holdings
SNTI· Manufacturing· Fiscal year ends in December
CEO pay in FY2024Stock -46.8% in FY2024
Timothy Lu, M.D., Ph.D. is the CEO of Senti Biosciences Holdings and was paid $930.7K in FY2024 (Dec), down 45%.
Pay$100 in the stock at the end of FY21 → $4
Executives3
See all- 1Timothy Lu, M.D., Ph.D.Chief Executive OfficerFY2024
- 2Kanya Rajangam, M.D., Ph.D.President, Head of Research and Development and Chief Medical OfficerFY2024
- 3Yvonne LiInterim Chief Financial OfficerFY2024
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allSenti Biosciences Holdings paid its 3 named executives $2.1M in total in FY2024 (Dec). CEO Timothy Lu, M.D., Ph.D. was paid $930.7K of that.
| Name | |||
|---|---|---|---|
| Timothy Lu, M.D., Ph.D.Chief Executive Officer | |||
| Kanya Rajangam, M.D., Ph.D.President, Head of Research and Development and Chief Medical Officer | |||
| Yvonne LiInterim Chief Financial Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Senti Biosciences Holdings. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Activity
Filings5
See all| Annual report | 10-K | Mar 27, 2026 | FY2025 |
| Annual report | 10-K | Mar 20, 2025 | FY2024 |
| Proxy statement | DEF 14A | Jan 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | May 29, 2024 | FY2023 |
| Annual report | 10-K | Mar 21, 2024 | FY2023 |
